See more : The ODP Corporation (ODP) Income Statement Analysis – Financial Results
Complete financial analysis of BELLUS Health Inc. (BLU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BELLUS Health Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Patagonia Gold Corp. (PGDC.V) Income Statement Analysis – Financial Results
- Kernex Microsystems (India) Limited (KERNEX.NS) Income Statement Analysis – Financial Results
- Lion Corporation (4912.T) Income Statement Analysis – Financial Results
- Strasbaugh (STRB) Income Statement Analysis – Financial Results
- China Clean Energy Inc. (CCGY) Income Statement Analysis – Financial Results
BELLUS Health Inc. (BLU)
About BELLUS Health Inc.
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16.00K | 16.00K | 15.00K | 26.79K | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.12M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.74M | 2.91M | 109.80K | 0.00 | 2.25M | 5.52M | 118.83K |
| Cost of Revenue | 3.51B | 2.22B | 1.43B | 994.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -137.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 693.62K | -470.29K | 0.00 | 0.00 | -1.16M | 0.00 | 0.00 |
| Gross Profit | -3.51B | -2.22B | -1.43B | -994.49M | 25.70K | 131.21K | 1.41M | 2.90M | 2.05M | 2.26M | 2.31M | 3.00M | 2.41M | -116.00K | 584.00K | 1.51M | 2.05M | 3.38M | 109.80K | 0.00 | 3.41M | 5.52M | 118.83K |
| Gross Profit Ratio | -21,967,104.08% | -13,887,173.94% | -9,536,119.55% | -3,711,740.75% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 106.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.71% | 116.14% | 100.00% | 0.00% | 151.65% | 100.00% | 100.00% |
| Research & Development | 58.89M | 59.79M | 23.73M | 20.00M | 5.28M | 2.87M | 1.13M | 931.76K | 1.46M | 1.19M | 998.16K | 1.29M | 7.05M | 10.04M | 23.60M | 55.45M | 49.54M | 40.61M | 24.42M | 5.71M | 8.03M | 6.56M | 3.19M |
| General & Administrative | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 0.00 | 7.69M | 8.57M | 11.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 611.90K | 3.71M | 6.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.50M | 14.26M | 9.74M | 6.68M | 2.50M | 2.01M | 1.95M | 2.25M | 2.71M | 4.01M | 4.99M | 3.47M | 8.30M | 12.28M | 18.45M | 15.17M | 14.67M | 23.25M | 18.29M | 5.75M | 2.44M | 396.43K | 1.02M |
| Other Expenses | -491.00K | -754.00K | -507.00K | -543.53K | -479.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 653.38K | 5.34M | -5.05M | 13.11M | 1.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 65.73M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Cost & Expenses | 77.90M | 73.30M | 32.96M | 26.13M | 7.30M | 4.65M | 2.97M | 2.98M | 4.17M | 5.21M | 5.95M | 4.76M | 17.10M | 21.00M | 46.24M | 70.16M | 66.42M | 66.60M | 44.41M | 11.95M | 11.06M | 7.23M | 4.43M |
| Interest Income | 5.08M | 233.00K | 1.05M | 1.16M | 265.78K | 63.62K | 74.40K | 104.49K | 170.56K | 189.71K | 137.71K | 105.78K | 151.98K | 102.00K | 907.00K | 0.00 | 2.36M | 2.08M | 0.00 | 520.42K | 1.14M | 0.00 | 0.00 |
| Interest Expense | 78.00K | 55.00K | 39.00K | 22.97K | 3.67K | 8.75K | 8.18K | 7.93K | 89.59K | 133.36K | 220.14K | 333.01K | 526.92K | 324.00K | 271.00K | 0.00 | 151.45K | 461.68K | 0.00 | 46.37K | 232.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.12M | 426.00K | 1.22M | 1.28M | 325.25K | 63.62K | 49.10K | 104.49K | 345.43K | 658.36K | -17.49M | 45.05K | 1.47M | 693.00K | 1.88M | 399.00K | 335.82K | 2.60M | 1.70M | 497.67K | 585.56K | 278.82K | 224.15K |
| EBITDA | -72.76M | -72.86M | -31.72M | -24.82M | -6.95M | -4.46M | -1.51M | 28.10K | -1.78M | -2.43M | -21.12M | -1.71M | -13.22M | -7.21M | -46.07M | -66.97M | -62.16M | -60.94M | -42.60M | -11.46M | -8.22M | -1.44M | -4.09M |
| EBITDA Ratio | -454,768.75% | -455,362.50% | -211,453.33% | -92,637.22% | -27,038.13% | -3,396.99% | -107.29% | 0.97% | -87.04% | -114.72% | -914.36% | -56.95% | -549.21% | 6,215.52% | -7,888.36% | -4,443.66% | -2,266.69% | -2,091.58% | -38,800.14% | 0.00% | -365.10% | -26.07% | -3,440.36% |
| Operating Income | -77.88M | -73.28M | -32.94M | -26.10M | -7.27M | -4.52M | -1.56M | -76.39K | -2.13M | -3.09M | -3.64M | -1.76M | -14.69M | -21.12M | -45.66M | -68.66M | -63.68M | -63.69M | -44.30M | -11.95M | -8.81M | -1.72M | -4.31M |
| Operating Income Ratio | -486,768.75% | -458,025.00% | -219,613.33% | -97,431.66% | -28,303.89% | -3,445.47% | -110.78% | -2.63% | -103.91% | -145.79% | -157.40% | -58.45% | -610.09% | 18,204.31% | -7,817.64% | -4,555.81% | -2,321.87% | -2,185.81% | -40,350.15% | 0.00% | -391.10% | -31.13% | -3,629.00% |
| Total Other Income/Expenses | 1.86M | 1.86M | 1.19M | -280.19K | 603.51K | 3.08M | -86.30K | 348.78K | 389.37K | 2.18M | -9.60M | 5.34M | -5.05M | 12.89M | -2.57M | -12.42M | -999.45K | 1.38M | 714.67K | -1.35M | 74.51K | 0.00 | 316.65K |
| Income Before Tax | -76.02M | -71.42M | -31.76M | -26.39M | -6.67M | -1.44M | -1.65M | 272.40K | -1.74M | -911.93K | -13.24M | 3.58M | -19.73M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -13.30M | -8.73M | 0.00 | -4.00M |
| Income Before Tax Ratio | -475,125.00% | -446,393.75% | -211,713.33% | -98,477.40% | -25,955.23% | -1,098.79% | -116.90% | 9.39% | -84.89% | -43.04% | -573.11% | 119.24% | -819.68% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -387.79% | 0.00% | -3,362.52% |
| Income Tax Expense | 60.00K | -199.00K | 39.00K | 22.97K | -607.18K | 48.51K | 11.16K | -19.46K | -42.21K | -617.97K | 18.44M | 227.23K | 374.94K | 13.44M | 1.32M | -1.94M | -1.50M | -2.04M | -626.83K | -365.56K | 152.98K | 58.14K | -227.53K |
| Net Income | -76.08M | -71.22M | -31.80M | -26.41M | -6.06M | -1.49M | -1.61M | 145.57K | -1.66M | -818.96K | -13.32M | 3.35M | -20.11M | -8.23M | -48.22M | -81.07M | -64.68M | -62.31M | -43.59M | -12.93M | -8.89M | -1.78M | -3.77M |
| Net Income Ratio | -475,500.00% | -445,150.00% | -211,973.33% | -98,563.12% | -23,592.29% | -1,135.76% | -114.05% | 5.02% | -81.27% | -38.65% | -576.81% | 111.68% | -835.26% | 7,092.24% | -8,257.36% | -5,379.76% | -2,358.31% | -2,138.42% | -39,699.24% | 0.00% | -394.58% | -32.18% | -3,171.04% |
| EPS | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | 1.38 | -10.28 | -6.34 | -105.15 | -198.86 | -181.01 | -196.26 | -156.38 | -52.10 | -53.29 | -11.00 | -32.16 |
| EPS Diluted | -0.66 | -0.90 | -0.54 | -0.09 | -0.18 | -0.08 | -0.10 | 0.01 | -0.13 | -0.06 | -1.48 | -0.67 | -10.28 | -6.30 | -105.15 | -198.86 | -181.01 | -187.15 | -137.04 | -44.64 | -49.86 | -11.00 | -32.16 |
| Weighted Avg Shares Out | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 2.47M | 1.96M | 1.30M | 458.62K | 407.69K | 357.31K | 317.48K | 278.73K | 248.27K | 166.73K | 161.45K | 117.17K |
| Weighted Avg Shares Out (Dil) | 115.36M | 79.32M | 59.02M | 294.74M | 33.62M | 19.07M | 16.22M | 13.17M | 13.17M | 13.17M | 8.98M | 6.04M | 1.96M | 1.31M | 458.62K | 407.69K | 357.31K | 332.93K | 318.06K | 289.73K | 178.21K | 161.45K | 117.17K |
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
GSK added to a series of recent takeovers Tuesday with the $2 billion acquisition of Bellus Health. But BLU stock and GSK stock diverged.
Bellus Health's stock climbs on GSK deal, while Goldman Sachs is hurt by a revenue miss
Here are some of the biggest movers on Tuesday:
GSK pays £1.6bn for Canada's Bellus Health
GSK PLC (LSE:GSK, NYSE:GSK) has paid around £1.6bn for Bellus Health (TSX:BLU) Inc, a Canada-based, late-stage biopharmaceutical company which specialises in respiratory treatments. The pharmaceuticals giant said the deal further strengthens specialty its medicines and respiratory pipeline with camlipixant, a highly...
GSK to acquire U.S.-based BELLUS Health for $14.75 per share
GSK PLC said Tuesday that it has reached an agreement to buy the late-stage biopharmaceutical company Bellus Health Inc. BLU, +3.08% BLU, +2.83% for $14.75 a share in cash, representing a total equity value of around $2.0 billion.
Wall Street Analysts Think Bellus (BLU) Could Surge 156.01%: Read This Before Placing a Bet
The mean of analysts' price targets for Bellus (BLU) points to a 156% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in...
BELLUS Health Reports Year 2022 Financial Results and Business Highlights
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic...
BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc.
Bellus Health: Building Momentum Around CALM, SOOTHE Studies
Refractory chronic cough remains as a complex condition that requires a medical breakthrough for treatment. BELLUS Health Inc. is pushing ahead on this front, with recent support from evidence in its recent clinical trials.
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Source: https://incomestatements.info
Category: Stock Reports